Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

• Status: Completed
• Trial end date: 2018-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and (2) oral glucose tolerance and beta cell function. Dapagliflozin is a potent, highly specific inhibitor of renal glucose transport [SGLT2].

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Dapagliflozin; Insulin

Criteria

Inclusion Criteria:

• T2DM

• Drug Naive Or On Oral Therapy

Exclusion Criteria:

• Insulin Treatment

• Major Organ Disease